Biomedical innovation has become riskier, more expensive and more difficult to finance with traditional sources such as private and public equity. Here we propose a financial structure in which a large number of biomedical programs at various stages of development are funded by a single entity to substantially reduce the portfolio's risk. The portfolio entity can finance its activities by issuing debt, a critical advantage because a much larger pool of capital is available for investment in debt versus equity. By employing financial engineering techniques such as securitization, it can raise even greater amounts of more-patient capital. In a simulation using historical data for new molecular entities in oncology from 1990 to 2011, we find that megafunds of $5–15 billion may yield average investment returns of 8.9–11.4% for equity holders and 5–8% for 'research-backed obligation' holders, which are lower than typical venture-capital hurdle rates but attractive to pension funds, insurance companies and other large institutional investors.
At a glance
- Science Business: The Promise, the Reality, and the Future of Biotech (Harvard Business School Press, Boston, Massachusetts, USA, 2006).
- The evolution of science-based business: innovating how we innovate. Working Paper 10-062 (Harvard Business School, 2010). <http://www.hbs.edu/research/pdf/10-062.pdf>
- Profile: Stelios Papadopoulos. Nat. Biotechnol. 29, 184 (2012).
- How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat. Rev. Drug Discov. 9, 203–214 (2010). et al.
- Anonymous. World Preview 2016 (Evaluate Pharma, 2010).
- Where have all the IPOs gone? Preprint at <http://ssrn.com/abstract=1954788> (2012). , &
- Biotech's wellspring: a survey of the health of the private sector. Nat. Biotechnol. 30, 395–400 (2012).
- Financing risk and innovation. Preprint at <http://ssrn.com/abstract=1657937> (2011). &
- Investment cycles and startup innovation. Preprint at <http://ssrn.com/abstract=1950581> (2011). &
- Financial Innovations Lab. Fixes in financing: financial innovation for translational research (Milken Institute, 2012). <http://www.milkeninstitute.org/pdf/FixesInFinancing.pdf>.
- Continuous-Time Finance (Blackwell Publishing, Ltd., Oxford, UK, 1990).
- Principles of Financial Engineering (Elsevier, Burlington, Massachusetts, USA, 2008).
- Anonymous. US Key Stats (Securities Industry and Financial Markets Association, 2012). <http://www.sifma.org/uploadedFiles/Research/Statistics/StatisticsFiles/CM-US-Key-Stats-SIFMA.xls>.
- Valuation and risk management of collateralized debt obligations and related securities. Annu. Rev. Financial Econom. 3, 193–222 (2011). &
- Reading about the financial crisis: a 21–book review. J. Econ. Lit. 50, 151–178 (2012).
- Valuing government guarantees: Fannie and Freddie revisited. in Measuring and Managing Federal Financial Risk (eds. Danzon, P. & Nicholson, S.) 131–162 (University of Chicago Press, Chicago, 2011). &
- Rethinking Finance: New Perspectives on the Crisis (Russell Sage Foundation, New York, 2012). , &
- Reinhart, C. & Rogoff, K. This Time Is Different: Eight Centuries of Financial Folly (Princeton University Press, Princeton, New Jersey, USA, 2009).
- Pharmaceutical industry financial performance. Nat. Rev. Drug Discov. 8, 927–928 (2009).
- Lessons from 60 years of pharmaceutical innovation. Nat. Rev. Drug Discov. 8, 959–968 (2009).
- Private Equity, Venture Capital, and the Financing of Entrepreneurship: The Power of Active Investing (Wiley, Hoboken, New Jersey, USA, 2011). , &
- Cost of capital for pharmaceutical, biotechnology, and medical device firms. in The Oxford Handbook of the Economics of the Biopharmaceutical Industry (eds. Danzon, P. & Nicholson, S.) 75–99 (Oxford University Press, New York, 2012).
- Portfolio selection. J. Finance 7, 77–91 (1952).
- National Venture Capital Association. National Venture Capital Association Yearbook 2011 (Thomson Reuters, New York, 2011).
- Corporate Default and Recovery Rates, 1920–2010 (Moody's Investors Service, 2011).
- Federal Reserve Board of Governors. Federal Reserve statistical release: Table h.15519 h.15(519) selected interest rates (16 March 2012). <http://www.federalreserve.gov/releases/h15/20120326/>.
- Reasonable Rx: Solving the Drug Price Crisis (Pearson Education, Upper Saddle River, New Jersey, USA, 2008). &
- Ernst & Young. Beyond Borders: Global Biotechnology Report (Ernst and Young, New York, 2011).
- Active Credit Portfolio Management in Practice (John Wiley & Sons, Hoboken, New Jersey, USA, 2009). &
- American Cancer Society. Cancer Facts & Figures 2011 (American Cancer Society, Atlanta, Georgia, USA, 2011).
- American Cancer Society. Global Cancer Facts & Figures Edn. 2 (American Cancer Society, Atlanta, Georgia, USA, 2011).
- Oncology clinical trials—secrets of success. Biotech Now (23 February 2012). <http://www.biotech-now.org/business-and-investments/2012/02/oncology-clinical-trials-secrets-of-success>.
- The price of innovation: new estimates of drug development costs. J. Health Econ. 22, 151–185 (2003). , &
- Estimating the cost of new drug development: Is it really $802 million? Health Aff. 25, 420–428 (2006). &
- The cost of biopharmaceutical R&D: is biotech different? Managerial Decision Econom. 28, 469–479 (2007). &
- Standard & Poor's Rating Services. 2010 annual global corporate default study and rating transitions (Standard & Poor's, 2011). <http://www.standardandpoors.com/ratings/articles/en/us/?articleType=HTML&assetID=1245302234237>.
- National Association of State Retirement Administrators. NASRA issue brief: public pension plan investment returns (NASRA, 2012). <http://www.nasra.org/resources/issuebrief120626.pdf>.
- United States Department of the Treasury. Legacy Securities Public-Private Investment Program: Program Update—Quarter Ended March 31, 2012 (US Treasury, Washington, DC, USA, 2012).